Cargando…

CSF β-amyloid and white matter damage: unravelling the neuropathology of Alzheimer’s disease

Detalles Bibliográficos
Autor principal:	Sousa Alves, Gilberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869445/ https://www.ncbi.nlm.nih.gov/pubmed/29248895 http://dx.doi.org/10.1136/jnnp-2017-317053

Ejemplares similares

Narrative impairment, white matter damage and CSF biomarkers in the Alzheimer’s disease spectrum
por: Drummond, Claudia, et al.
Publicado: (2019)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
por: Wang, Jun, et al.
Publicado: (2011)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

White matter hypointensities and hyperintensities have equivalent correlations with age and CSF β‐amyloid in the nondemented elderly
por: Wei, Ke, et al.
Publicado: (2019)

Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease
por: Nicoll, James A R, et al.
Publicado: (2019)

Alzheimer’s disease neuropathological change three decades after iatrogenic amyloid-β transmission
por: Jaunmuktane, Zane, et al.
Publicado: (2021)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

CSF T-Tau/Aβ(42) Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer’s Disease
por: Bendlin, Barbara B., et al.
Publicado: (2012)

Microvascular contributions to white matter injury in Alzheimer’s disease
por: Bagi, Zsolt, et al.
Publicado: (2023)

Cognitive reserve, neuropathology, and progression towards Alzheimer’s disease
por: Nelson, Monica E., et al.
Publicado: (2023)

An intrinsically disordered protein, osteopontin, driving neuropathology in Alzheimer’s dementia
por: Steinman, Lawrence
Publicado: (2023)

White matter neuron biology and neuropathology in schizophrenia
por: Duchatel, Ryan J., et al.
Publicado: (2019)

White Matter Damage in Alzheimer’s Disease: Contribution of Oligodendrocytes
por: Zhou, Jinyu, et al.
Publicado: (2022)

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
por: Grothe, Michel J., et al.
Publicado: (2021)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Reduced CSF Water Influx in Alzheimer’s Disease Supporting the β-Amyloid Clearance Hypothesis
por: Suzuki, Yuji, et al.
Publicado: (2015)

CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia
por: Heywood, Wendy E., et al.
Publicado: (2018)

BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
por: Kim, Jun Pyo, et al.
Publicado: (2021)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia
por: Gordon, Brian A., et al.
Publicado: (2015)

The neuropathological landscape of Hispanic and non-Hispanic White decedents with Alzheimer disease
por: Scalco, Rebeca, et al.
Publicado: (2023)

Selectivity to amyloid-β precursor protein cleavage provides hope against Alzheimer's
por: Tomita, Taisuke, et al.
Publicado: (2011)

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
por: Amadoru, Sanka, et al.
Publicado: (2020)

β-Amyloid PET and neuropathology in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2020)

Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
por: Kim, Jun Pyo, et al.
Publicado: (2022)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Amyloid β and Alzheimer’s Disease: Molecular Updates from Physiology to Pathology
por: Giuffrida, Maria Laura
Publicado: (2023)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
por: Li, Yi, et al.
Publicado: (2022)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Increased CSF NFL in Non-demented Parkinson’s Disease Subjects Reflects Early White Matter Damage
por: Papuć, Ewa, et al.
Publicado: (2020)

The Effects of CSF Neurogranin and APOE ε4 on Cognition and Neuropathology in Mild Cognitive Impairment and Alzheimer’s Disease
por: Fan, Yulan, et al.
Publicado: (2021)

In vivo Characterization of Biochemical Variants of Amyloid-β in Subjects with Idiopathic Normal Pressure Hydrocephalus and Alzheimer’s Disease Neuropathological Change
por: Libard, Sylwia, et al.
Publicado: (2021)

Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer’s disease
por: Patrick, Ellis, et al.
Publicado: (2017)

Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model
por: Cho, Soo Min, et al.
Publicado: (2014)

CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022)

Neuropathological assessment and validation of mouse models for Alzheimer's disease: applying NIA-AA guidelines
por: Keene, C. Dirk, et al.
Publicado: (2016)

Breaking the Cycle, Cholesterol Cycling, and Synapse Damage in Response to Amyloid-β
por: Bate, Clive
Publicado: (2017)

Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer’s Disease
por: Lopez-Font, Inmaculada, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6vv28qcikedbio0c8ikas7dcn9